Novo Nordisk says it is gradually phasing out human insulin pens globally
Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...
Zacks.com on MSN8m
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate
Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.
health-e13h
MSF condemns Novo Nordisk double standard in diabetes care
The decision by Novo Nordisk to discontinue the insulin pens will force patients to revert to syringes, complicating diabetes care for millions of people.
Why maker of ‘magic’ weight-loss drug semaglutide wants copies banned
US Food and Drug Administration (FDA) regulations allow human drug compounding — in which licensed pharmacists or physicians ...